BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38327192)

  • 1. "RIPping" off Pancreas Cancer's Blockage of Immune Surveillance.
    Liu X; Sells BE; DeNardo DG
    Cancer Discov; 2024 Feb; 14(2):208-210. PubMed ID: 38327192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptor-interacting Protein Kinase 2 Is an Immunotherapy Target in Pancreatic Cancer.
    Sang W; Zhou Y; Chen H; Yu C; Dai L; Liu Z; Chen L; Fang Y; Ma P; Wu X; Kong H; Liao W; Jiang H; Qian J; Wang D; Liu YH
    Cancer Discov; 2024 Feb; 14(2):326-347. PubMed ID: 37824278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
    Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
    Front Immunol; 2018; 9():1878. PubMed ID: 30158932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy.
    Principe DR; Narbutis M; Kumar S; Park A; Viswakarma N; Dorman MJ; Kamath SD; Grippo PJ; Fishel ML; Hwang RF; Thummuri D; Underwood PW; Munshi HG; Trevino JG; Rana A
    Cancer Res; 2020 Aug; 80(15):3101-3115. PubMed ID: 32238357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MHC class II molecules on pancreatic cancer cells indicate a potential for neo-antigen-based immunotherapy.
    Baleeiro RB; Bouwens CJ; Liu P; Di Gioia C; Dunmall LSC; Nagano A; Gangeswaran R; Chelala C; Kocher HM; Lemoine NR; Wang Y
    Oncoimmunology; 2022; 11(1):2080329. PubMed ID: 35655709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined MEK and STAT3 Inhibition Uncovers Stromal Plasticity by Enriching for Cancer-Associated Fibroblasts With Mesenchymal Stem Cell-Like Features to Overcome Immunotherapy Resistance in Pancreatic Cancer.
    Datta J; Dai X; Bianchi A; De Castro Silva I; Mehra S; Garrido VT; Lamichhane P; Singh SP; Zhou Z; Dosch AR; Messaggio F; Ban Y; Umland O; Hosein PJ; Nagathihalli NS; Merchant NB
    Gastroenterology; 2022 Dec; 163(6):1593-1612. PubMed ID: 35948109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I.
    Yamamoto K; Venida A; Yano J; Biancur DE; Kakiuchi M; Gupta S; Sohn ASW; Mukhopadhyay S; Lin EY; Parker SJ; Banh RS; Paulo JA; Wen KW; Debnath J; Kim GE; Mancias JD; Fearon DT; Perera RM; Kimmelman AC
    Nature; 2020 May; 581(7806):100-105. PubMed ID: 32376951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy.
    Yang J; Zhang Q; Wang J; Lou Y; Hong Z; Wei S; Sun K; Wang J; Chen Y; Sheng J; Su W; Bai X; Liang T
    EBioMedicine; 2022 Apr; 78():103958. PubMed ID: 35316682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Context-Dependent Immune Responses Explain Pancreatic Cancer Immunoresistance.
    Bednar F; Pasca di Magliano M
    Cancer Cell; 2020 Mar; 37(3):261-263. PubMed ID: 32183944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy.
    Li E; Huang X; Zhang G; Liang T
    J Exp Clin Cancer Res; 2021 Sep; 40(1):279. PubMed ID: 34479614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Galectin-9 and PD-L1 antibody blockade combination therapy inhibits tumour progression in pancreatic cancer.
    Li E; Xu J; Chen Q; Zhang X; Xu X; Liang T
    Immunotherapy; 2023 Feb; 15(3):135-147. PubMed ID: 36779368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interplay between MAP kinases and tumor microenvironment: Opportunity for immunotherapy in pancreatic cancer.
    Kumar S; Singh SK; Srivastava P; Suresh S; Rana B; Rana A
    Adv Cancer Res; 2023; 159():113-143. PubMed ID: 37268394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
    Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
    J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unraveling the impact of sialic acids on the immune landscape and immunotherapy efficacy in pancreatic cancer.
    Boelaars K; Goossens-Kruijssen L; Wang D; de Winde CM; Rodriguez E; Lindijer D; Springer B; van der Haar Àvila I; de Haas A; Wehry L; Boon L; Mebius RE; van Montfoort N; Wuhrer M; den Haan JMM; van Vliet SJ; van Kooyk Y
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37940346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feeding cancer's sweet tooth: specialized tumour vasculature shuttles glucose in pancreatic ductal adenocarcinoma.
    Dudley AC; Bautch VL
    J Pathol; 2015 Jun; 236(2):133-5. PubMed ID: 25727340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoplastic "Black Ops": cancer's subversive tactics in overcoming host defenses.
    Biragyn A; Longo DL
    Semin Cancer Biol; 2012 Feb; 22(1):50-9. PubMed ID: 22257681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IRAK4 Signaling Drives Resistance to Checkpoint Immunotherapy in Pancreatic Ductal Adenocarcinoma.
    Somani VK; Zhang D; Dodhiawala PB; Lander VE; Liu X; Kang LI; Chen HP; Knolhoff BL; Li L; Grierson PM; Ruzinova MB; DeNardo DG; Lim KH
    Gastroenterology; 2022 Jun; 162(7):2047-2062. PubMed ID: 35271824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape.
    Lu C; Liu Z; Klement JD; Yang D; Merting AD; Poschel D; Albers T; Waller JL; Shi H; Liu K
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity.
    Moral JA; Leung J; Rojas LA; Ruan J; Zhao J; Sethna Z; Ramnarain A; Gasmi B; Gururajan M; Redmond D; Askan G; Bhanot U; Elyada E; Park Y; Tuveson DA; Gönen M; Leach SD; Wolchok JD; DeMatteo RP; Merghoub T; Balachandran VP
    Nature; 2020 Mar; 579(7797):130-135. PubMed ID: 32076273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.